Physician profile
Abid Bashir
NPI 1700822608
$2,684.79
in general payments reported to CMS, 2019-2025
26 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $97.15 · 2021: $225 · 2022: $532 · 2023: $286 · 2024: $715 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.19 |
| Education | $136.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $371.78 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Horizon Therapeutics Plc | $290.32 | 2020-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $214.86 | 2019-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $207.59 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $192.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $168.16 | 2022-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $130.24 | 2024 | |
| Travere Therapeutics, INC. | $128.65 | 2019-2025 | Filspari |
| Akebia Therapeutics INC | $128.28 | 2019-2024 | Auryxia, Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.73 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $122.06 | 2025 | Ozempic, Wegovy, Rybelsus |
| Mallinckrodt Hospital Products INC. | $93.26 | 2025 | Terlivaz |
| Vifor Pharma, INC. | $70.42 | 2020-2023 | Veltassa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $65.74 | 2019 | |
| Ani Pharmaceuticals, INC. | $62.12 | 2025 | Purified Cortrophin Gel |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50.03 | 2022-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $45.13 | 2021-2023 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $38.43 | 2025 | Empaveli |
| Opko Pharmaceuticals, LLC | $36.92 | 2021-2023 | Rayaldee |
| Genzyme Corporation | $27.30 | 2024 | |
| Athena Bioscience, LLC | $23.09 | 2025 | Nexiclon Xr |
| Daiichi Sankyo INC. | $22.18 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.87 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.58 | 2021 | |
| Calliditas Therapeutics US INC. | $17.28 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $16.02 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.